Literature DB >> 31839148

Computed Tomography Features of Cuspal Thrombosis and Subvalvular Tissue Ingrowth after Transcatheter Aortic Valve Implantation.

Hyun Jung Koo1, Jooae Choe1, Do-Yoon Kang2, Euihong Ko2, Jung-Min Ahn2, Duk-Woo Park2, Seung-Jung Park2, Ho Jin Kim3, Joon Bum Kim3, Suk Jung Choo3, Joon-Won Kang1, Dong Hyun Yang4.   

Abstract

Post-transcatheter aortic valve implantation (TAVI) computed tomography (CT) findings have not been fully elucidated, except hypoattenuating leaflet thickening (HALT). The objective of this study was to describe cardiac CT findings after TAVI, and investigate factors associated with HALT. This retrospective study included patients who underwent TAVI and post-TAVI cardiac CT scans. On CT, abnormal findings such as hypoattenuating subvalvular thickening (HAST), thrombus within the sinus of Valsalva, HALT, and leaflet motion limitation were thoroughly reviewed. Clinical and CT findings were compared between patients with HALT and those without HALT. Logistic regression analysis was performed to determine factors associated with HALT. A total of 138 patients (64 male, mean 78.5 ± 5.2 years of age) with post-TAVI CT scans were included. The median duration from TAVI to CT was 17.5 days (interquartile range, 3 to 390.8 days). HAST and thrombus within the sinus of Valsalva were detected in 32 (23%) and 5 (4%) patients, respectively. HALT and leaflet motion limitations were found in 25 (18%) and 20 (14%) of patients, respectively. Pannus was diagnosed in 2 patients. TAVI device implant duration (odds ratio [OR], 1.5; p = 0.01), hypertension (OR, 0.2; p = 0.03), and HAST (OR, 4.9; p = 0.003) were associated with HALT. Implant durations were longer in patients with HAST, HALT, or leaflet motion limitation (p < 0.05, for all). In conclusion, HAST, HALT, thrombus within the sinus of Valsalva, and leaflet motion limitation are not uncommon after TAVI. Implant duration, hypertension, and HAST are associated with HALT.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31839148     DOI: 10.1016/j.amjcard.2019.11.015

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Transcatheter Aortic Valve Leaflet Thrombosis: Prevalence, Management, and Future Directions.

Authors:  Makoto Nakashima; Hasan Jilaihawi
Journal:  Curr Cardiol Rep       Date:  2021-11-11       Impact factor: 2.931

2.  Repeated transcatheter aortic valve implantation for the treatment of a degenerated transcatheter aortic valve implantation valve (valve-in-valve technique): a case report.

Authors:  Vassileios Voudris; Ioannis Iakovou; Ilias Kosmas; Eftychia Sbarouni
Journal:  Eur Heart J Case Rep       Date:  2020-10-23

3.  Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement.

Authors:  Hanbit Park; Do-Yoon Kang; Jung-Min Ahn; Kyung Won Kim; Anthony Y T Wong; Simon C C Lam; Wei-Hsian Yin; Jeng Wei; Yung-Tsai Lee; Hsien-Li Kao; Mao-Shin Lin; Tsung-Yu Ko; Won-Jang Kim; Se Hun Kang; Euihong Ko; Dae-Hee Kim; Hyun Jung Koo; Dong Hyun Yang; Joon-Won Kang; Seung Chai Jung; Jae-Hong Lee; Sung-Cheol Yun; Seung-Jung Park; Duk-Woo Park
Journal:  BMJ Open       Date:  2021-01-05       Impact factor: 2.692

Review 4.  Residual Bioprosthetic Valve Immunogenicity: Forgotten, Not Lost.

Authors:  Paul Human; Deon Bezuidenhout; Elena Aikawa; Peter Zilla
Journal:  Front Cardiovasc Med       Date:  2022-01-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.